Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

NCT00610129 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors
Metastatic Neuroendocrine Tumors

Interventions

DRUG: MK-0646

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]